Clinical Trials
155 trialsPALANGI3
Centre Oscar Lambret
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
American University of Beirut Medical Center
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
TIKlet
University of Pisa
UKALL14
University College, London
DESTINY
University of Liverpool
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
First Affiliated Hospital, Sun Yat-Sen University
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
First Affiliated Hospital, Sun Yat-Sen University
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
University of Nebraska
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
PInNACLe
Australasian Leukaemia and Lymphoma Group
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
ImadGist
Centre Leon Berard
Entacapone Combination With Imatinib for Treatment of GIST
Xiangya Hospital of Central South University
Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Rutgers, The State University of New Jersey
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
ESPHALL
Rennes University Hospital
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Medical College of Wisconsin
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
CML0609
Gruppo Italiano Malattie EMatologiche dell'Adulto
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
M.D. Anderson Cancer Center
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Mansoura University
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Istituto Clinico Humanitas
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Dana-Farber Cancer Institute
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
University of California, San Francisco
NITMEC
Inova Health Care Services
LAMP-1
Medical University of South Carolina
SPIRIT
Poitiers University Hospital
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Yonsei University
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
ISAV
University of Milano Bicocca
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Alliance for Clinical Trials in Oncology
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
Imperial College London
MetAction
Oslo University Hospital
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
University Health Network, Toronto
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center